Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Bought by RK Asset Management LLC

RK Asset Management LLC lifted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 9.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 9,989 shares of the biopharmaceutical company’s stock after acquiring an additional 896 shares during the quarter. Regeneron Pharmaceuticals accounts for approximately 5.8% of RK Asset Management LLC’s portfolio, making the stock its 6th largest holding. RK Asset Management LLC’s holdings in Regeneron Pharmaceuticals were worth $7,115,000 at the end of the most recent quarter.

A number of other hedge funds have also recently added to or reduced their stakes in REGN. Rakuten Securities Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 380.0% in the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 19 shares during the period. Sachetta LLC lifted its holdings in Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 10 shares during the period. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $37,000. Finally, Ashton Thomas Private Wealth LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on REGN shares. Piper Sandler lowered their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. Barclays dropped their price objective on Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating for the company in a research note on Friday, November 1st. Leerink Partners reiterated a “market perform” rating and set a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $1,015.00 price target on shares of Regeneron Pharmaceuticals in a research note on Wednesday, October 23rd. Finally, JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. One research analyst has rated the stock with a sell rating, six have given a hold rating, sixteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Regeneron Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $1,052.90.

Regeneron Pharmaceuticals Stock Up 0.4 %

NASDAQ REGN traded up $2.96 during trading hours on Friday, reaching $718.15. 557,944 shares of the company traded hands, compared to its average volume of 518,522. The stock has a market capitalization of $78.92 billion, a PE ratio of 17.77, a PEG ratio of 2.19 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12 month low of $693.00 and a 12 month high of $1,211.20. The company has a 50 day moving average of $772.73 and a two-hundred day moving average of $976.16. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.